AB0550 CLINICAL AND PROGNOSTIC SIGNIFICANCE OF ANTINUCLEAR ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: FRENCH MULTICENTER RETROSPECTIVE STUDY

Background The antiphospholipid syndrome (APS) is defined by the development of vascular thrombosis, or pregnancy morbidity in presence persistent antibodies (APL). Antinuclear (ANA) can be detected primary APS patients without any clinical systemic autoimmune disease. ANA could confer a specific phenotype APS. Objectives To evaluate characteristics with antinuclear other disease (ANA-positive patients) comparison (ANA-negative APS) secondary associated lupus erythematosus (SLE-APS). Methods Clinical and biologic data from 195 were retrospectively collected. test was considered to positive when titers superior egal 1/80 dilution. ANA-positive did not fulfilled SLE ACR/EULAR classification criteria. Results 40 (21%) included, 77 (39%) autoantibodies 78 (40%) SLE-associated Patients presented arterial thrombosis 20 cases (51%) venous f 14 (41%), adverse obstetrical 19 (51%), non-criteria features noted (51%). had more non criteria manifestations than ANA-negative (48% versus 25%; p=0.01). triple APL positivity recurrences patients, respectively (59% 18%; p<0.001) (63% 36%; p<0.01). SLE-APS similar recurrences. Despite limited follow-up (28 months (11-50)) none develop SLE. Antiplatelet anticoagulant therapies for three groups. received immunomodulatory therapies. Conclusion enables individualize subset severe phenotype. Whereas does seem risk SLE, prospective studies longer are necessary, particular effect additional this Disclosure Interests None declared